Most patients with PC respond to androgen-ablation therapies, which exploit the androgen-sensitivity of PC cells by either lowering serum androgen levels or blocking androgen receptor (AR) activity, resulting in apoptotic cancer cell death. This evidence concerns the gene AR and pachyonychia congenita.